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Edited by Stuart FergusonAbstract Halocidin is an antimicrobial peptide isolated from
the hemocytes of the tunicate. Among the several known syn-
thetic halocidin analogues, di-K19Hc has been previously con-
ﬁrmed to have the most profound antibacterial activity against
antibiotic-resistant bacteria. This peptide has been considered
to be an eﬀective candidate for the development of a new type
of antibiotic. In this study, we have assessed the antifungal activ-
ity of di-K19Hc, against a panel of fungi including several strains
of Aspergillus and Candida. As a result, we determined that the
MICs of di-K19Hc against six Candida albicans and two Asper-
gillus species were below 4 and 16 lg/ml, respectively, thereby
indicating that di-K19Hc may be appropriate for the treatment
of several fungal diseases. We also conducted an investigation
into di-K19Hc’s mode of action against Candida albicans. Our
colony count assay showed that di-K19Hc killed C. albicans
within 30 s. Di-K19Hc bound to the surface of C. albicans via
a speciﬁc interaction with b-1,3-glucan, which is one of fungal
cell wall components. Di-K19Hc also induced the formation of
ion channels within the membrane of C. albicans, and eventually
observed cell death, which was conﬁrmed via measurements of
the K+ released from C. albicans cells which had been treated
with di-K19Hc, as well as by monitoring of the uptake of propi-
dium iodide into the C. albicans cells. This membrane-attacking
quality of di-K19Hc was also visualized via confocal laser and
scanning electron microscopy.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In the last two decades, the incidence of human fungal infec-
tions has increased dramatically, in parallel with the wide
spread of incurable infectious diseases associated with antibi-
otic-resistant bacteria. Fungal diseases have become a growing
threat, especially in immunocompromised patients, for which
few or no eﬀective drugs are currently available [1]. Accord-
ingly, a variety of studies have been conducted in an attempt
to isolate natural antifungal substances with potential pharma-
ceutical utility, and to develop and design new synthetic or
semi-synthetic drugs [2–4].
Antimicrobial peptides have recently become the focus of con-
siderable interest as a candidate for a new type of antibiotic, due*Corresponding author. Fax: +82 41 548 6231.
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resistant to conventional antibiotics, as well as their broad-spec-
trum activity [5]. Since the ﬁrst identiﬁcation of cecropin [6] and
defensin [7] in insect hemolymph and human neutrophils,
respectively, more than 880 antimicrobial peptides have been
isolated from awide variety of organisms, including vertebrates,
invertebrates, and plants [8]. Tunicates, simple marine proto-
chordates, have recently been reported to harbor several antimi-
crobial peptides in their hemocytes, including halocidin [9],
dicynthaurin [10], clavanins [11], styelins [12], clavaspirin [13],
plicatamide [14] and halocyamine [15]. They were also puriﬁed
and studied in order to characterize the relationship between
their structure and activity. Among these compounds, the haloc-
idin detected in Halocynthia aurantium appears to exhibit the
most potent antibacterial activity. It is a heterodimeric peptide
consisting of two a-helical monomers with 18 and 15 amino acid
residues, referred to as 18Hc and 15Hc, respectively. From the
structure of 18Hc, several synthetic congeners have been de-
signed and evaluated with regard to their antibacterial activities
against a variety of antibiotic-resistant bacteria, under diverse
conditions [16]. As a result of these trials, it was determined that
di-K19Hc, a homodimeric version of a synthetic peptide
(K19Hc), formed via the addition of a lysine (K) residue to the
N-terminus of 18Hc, exhibited profound antibacterial eﬀects,
andwas also shown to exhibitmuch alleviated hemolytic activity
against human erythrocytes. Therefore, di-K19Hc was consid-
ered to be the most appropriate candidate for the development
of a novel peptide antibiotic, although the mechanisms underly-
ing the aforementioned activities remained to be elucidated. In
the present study, we tested di-K19Hc with regard to antifungal
activities against 13 fungal strains, including two major genera,
the Candida and Aspergillus strains, which are responsible for
the majority of fungal pathogenic infections. We also attempted
to determine themanner inwhich di-K19Hc exerts its antifungal
eﬀects against C. albicans. In this paper, we describe the anti-
fungal activity of di-K19Hc, and the mechanism underlying this
eﬀect.2. Materials and methods
2.1. Peptides
K19Hc and P18, a cecropin-magainin hybrid [17], were synthesized
using an automated solid-phase peptide synthesizer (Pioneer Applied
Biosystems, Foster, CA), at the Korea Basic Science Institute. The
Buforin II [18] used in this study was purchased from Sigma (St. Louis,
USA). All of the peptides were then re-puriﬁed via C18 reverse-phase
(RP) high-pressure liquid chromatography (HPLC). In order toblished by Elsevier B.V. All rights reserved.
Fig. 1. RP-HPLC proﬁles and tricine SDS–PAGE analysis for puriﬁed
K19Hc and di-K19Hc. Each of the HPLC iterations was performed
under the same conditions. The HPLC fractions were eluted in various
linear gradients of acetonitrile containing 0.1% triﬂuoroacetic acid
(TFA). For the ﬁrst 10 min after sample loading, the C18 column
(Vydac 218TP54: The Separation Group, Hesperia, CA, USA) was
washed with 5% acetonitrile at a 0.5 ml/min ﬂow rate. Then the
acetonitrile concentration linearly increased by 1%/min, for 60 min.
K19Hc was eluted at 45% of acetonitrile (A). Di-K19Hc was eluted at
50% of acetonitrile (B). The right panel shows a Coomassie blue-
stained, 16.5% tricine SDS–PAGE gel, containing puriﬁed K19Hc and
di-K19Hc. Lane M, standard molecular weight markers; lane 1,
K19Hc; lane 2, di-K19Hc. Samples were electrophoresed under non-
reducing condition. A Model Mini-Protean 3 Cell (Bio-Rad) was used
to perform tricine SDS–PAGE [19].
W.S. Jang et al. / FEBS Letters 580 (2006) 1490–1496 1491prepare the di-K19Hc, the puriﬁed K19Hc was exposed to 0.1 M
ammonium bicarbonate (1 mg/ml) for at least 72 h at room tempera-
ture. Fig. 1 shows the HPLC proﬁles of the puriﬁcation of K19Hc
and di-K19Hc. The purity of the peptides was monitored via HPLC
proﬁle and tricine SDS–PAGE analysis (right panel in Fig. 1) [19], con-
ducted under non-reducing conditions. The puriﬁed peptides were
completely dried and stored at 70 C until used. When necessary,
the peptides were dissolved in acidiﬁed distilled water (0.01% acetic
acid), and the peptide concentrations were then evaluated using the
bicinchoninic acid technique (Pierce, Rockford, IL), with bovine serum
albumin employed as a standard protein.2.2. MICs of the peptides against fungi
The minimum inhibitory concentrations (MICs) [20] for di-K19Hc,
K19Hc, buforin II, and P18 against 13 fungal strains were determined
in accordance with the methods developed by the National Committee
on Clinical Laboratory Standards (NCCLS) [21], with some modiﬁca-
tions. Two fungal spores (Pyricularia grisea KACC40425 and Fusar-
ium oxysporum KACC40902) and one yeast (Geotrichum candidum
KACC40354) were grown in 1/2 Potato Dextrose Broth (Difco,
USA), and two other yeast strains (Cryptococcus neoformans
KCCM50544 and Trichosporon beigelli KCTC7707) were cultivated
in YM broth (Difco) for 48 h at 30 C. The Candida (C. albicans
KCTC7121, 7122, 7270, 7728, 7729, 7965) and Aspergillus (A. terreus
KCTC6178, A. niger KCTC6461) strains were cultured in Sabouraud
Dextrose Broth (SDB: Difco) for 24 and 72 h, respectively, at 30 C.
The SDB was prepared in 10 mM sodium phosphate buﬀer, at a pH
of 7.0. Each of the ﬁlamentous or yeast-phase fungal strains was di-
luted in its corresponding broth, to a ﬁnal concentration of
2 · 103 spores/ml or cells/ml, respectively. The numbers of spores or
yeasts were counted using a hemocytometer. Stock peptide solutions
were prepared to a concentration of 640 lg/ml in 0.01% acetic acid,
and were then serially diluted twofold, to 10 lg/ml. 100 ll aliquots of
the diluted culture media were dispensed into the wells of 96-well poly-
propylene microtiter plates (Costar 3790, Corning, NY), to which pep-
tide solution (11 ll) was then added. In the experiments conducted to
assess the candidacidal activity of peptides in the presence of salt, we
used SDB supplemented with up to 200 mM NaCl for the culture med-
ium, which was mixed with the peptide solution. The antifungal activ-ities were evaluated after 48 h of incubation at 30 C, by observations
of visible turbidity in each of the wells in the plates. The MIC values
were expressed as intervals (a  b), in which a represents the highest
tested concentration at which microbes continue to grow, and b is
the lowest concentration at which growth inhibition can be detected.
These experiments were repeated at least three times, and each was
conducted on a diﬀerent day.
2.3. Colony count analysis for the candidacidal activity of di-K19Hc
100 ll of a predetermined concentration of di-K19Hc was mixed
with 1 ml aliquots of yeast-phase C. albicans (3 · 107 colony forming
units/ml, CFU/ml), in 10 mM sterile sodium phosphate buﬀer (pH
7.4). The mixtures, in ﬁnal volumes of 1.1 ml, were then incubated in
a shaking incubator at 30 C, and 100 ll aliquots were removed at pre-
determined intervals. Each of the aliquots directly or after dilution was
plated on SDB agar consisting of 1% agarose and 3% SDB powder in
10 mM sodium phosphate buﬀer, at neutral pH. The resultant colonies
were then counted, after being incubated overnight at 30 C.
2.4. Potassium eﬄux
The K+ eﬄux from the di-K19Hc-treated C. albicans cells was mea-
sured with An Istek model 735 pH/ISE meter, ﬁtted with a potassium
ion electrode (pHoenix Electrode, USA), as was described in the study
of Orlov et al. [22]. In brief, the C. albicans KCTC7122 cells were cul-
tured overnight in 50 ml of SDB, at 30 C. The cells were washed three
times with 10 mM sodium phosphate buﬀer, pH 7.4, and resuspended
at a concentration of 3.5 · 107 cells/ml in the same buﬀer. One milli-
liter aliquots of these C. albicans suspensions were then incubated with
100 ll of di-K19Hc (1 mg/ml in 0.01% acetic acid) at 30 C, for prede-
termined times. After a 30-s spindown at 12000 rpm, 9 ml of distilled
water was added to the supernatant of each of the samples. The total
K+ eﬄux was then determined, as the concentration of K+ released
from the C. albicans after the disruption of the samples via prolonged
sonication (3 min at 60% power: Gera¨te-Type UW 2200, Bandelin
Electronic, Berlin, Germany). These experiments were repeated ﬁve
times, and the mean values were utilized in the construction of the
graph. The percent K+ release was then calculated, according to the
following equation: K+ release (%) = ([K+] of sample  [K+] of pep-
tide-free control)/([K+] of 100% control  [K+] of peptide-free con-
trol) · 100.
2.5. FACScan analysis
The integrity of the yeast membranes after peptide treatment was
determined by FACScan analysis, via nuclear staining with propidium
iodide (PI; Sigma) as was described by Yeaman et al. [23]. In brief, C.
albicans KCTC7122 was ﬁrst harvested after being cultured overnight,
and then washed twice with phosphate-buﬀered saline (PBS, 1.47 mM
KH2PO4, 10 mM Na2HPO4 Æ 12H2O, 2.7 mM KCl, 137 mM NaCl, pH
7.4). The washed cells (2 · 105 cells) were mixed with peptides at a con-
centration of 3.12 lg/ml in PBS, then incubated for 10 min at 30 C.
The peptide-treated cells were incubated in PI solution (50 lg/ml ﬁnal
concentration) for 30 min at 4 C. After incubation, the unbound dye
was removed via the excessive washing of cells with PBS. The PI was
excited at 488 nm with an argon laser, and the resulting ﬂuorescence
emission was collected through a P620 nm long pass ﬁlter. Flow
cytometry analysis was conducted using a FACScan instrument
(Becton–Dickinson, San Jose, CA).
2.6. Assay for binding of di-K19Hc to the component of fungal cell wall
Binding property of di-K19Hc to the surface of C. albicans was
examined by assessing the eﬀect of fungal cell wall components on
the anti-Candida activity of di-K19Hc in ultrasensitive radial diﬀusion
assay [9]. 20 ll of 1.25 mg/ml di-K19Hc solution was added to 80 ll of
laminarin (b-1,3-glucan polymer; Sigma), pustulan (b-1,6-glucan poly-
mer; Calbiochem, La Jolla, USA) or mannan (mannose polymer; Sig-
ma), each of which was twofold serially diluted in 10 mM sodium
phosphate buﬀer (pH 7.4) ranged in concentration from 10 to
0.312 mg/ml and incubated for 4 h at 37 C. 5 ll samples were loaded
into 3 mm diameter wells that had been punched in underlay gels in
which the washed yeast-phase C. albicans (4 · 106 colony forming
units) were trapped. The underlay agars consisted of 9 mM sodium
phosphate, 1 mM sodium citrate buﬀer, 1% (w/v) agarose (Sigma),
and 0.3 mg of tryptic soy broth (TSB: Difco)/ml. After incubation at
able 1
equences of the antimicrobial peptides used in this study
sterisks (*) signify C-terminal amidation. Two cysteine residues
onnected by a disulﬁde linkage in the structure of di-K19Hc are
own in the box.
able 2
inimum inhibitory concentration (MIC, lg/ml) for antifungal
ctivity of di-K19Hc and control peptides
Di-K19Hc K19Hc P18 Buforin II
ilamentous fungi
. griseaa KACC40425 4–8 4–8 4–8 8–16
. oxysporum
KACC40902
4–8 8–16 4–8 8–16
. terreusb KCTC6178 8–16 >64 >64 >64




8–16 16–32 8–16 16–32
r. neoformansc
KCCM50544
16–32 16–32 32–64 32–64
. beigelli KCTC7707 2–4 4–8 2–4 16–32
. albicans KCTC7121 1–2 8–16 <1 32–64
. albicans KCTC7270 2–4 16–32 8–16 >64
. albicans KCTC7728 2–4 16–32 4–8 >64
. albicans KCTC7729 2–4 8–16 2–4 16–32
. albicans KCTC7965 2–4 16–32 32–64 >64
ACC, Korean Agricultural Culture Collection.
KCTC, Korean Collection for Type Cultures.
cKCCM, Korea Culture Center of Microorganisms.
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on the underlay gel. After the plates were incubated overnight at
37 C to allow surviving C. albicans cells to form colonies, the diame-
ters of clearing zones indicating antifungal activity were plotted against
polysaccharide concentrations. Experiments were performed in tripli-
cate, and mean values were used to make a graph.
2.7. Western blotting analysis
Acid urea–PAGE and Western blotting analyses were conducted in
accordance with the method described by Panyutich and Ganz [24]. In
the Western blotting experiments, we used an antiserum that had pre-
viously been generated via an injection of 18Hc into a rabbit [25]. In
brief, the samples were electrophoresed on acid urea–PAGE gels and
transferred to nitrocellulose membranes in Tris–glycine buﬀer
(25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3) at 100 V for
1 h. After transference, the membranes were equilibrated in Tris–buf-
fered saline (20 mM Tris, 500 mM NaCl, pH 7.5; TBS) for 10 min
and then incubated for 30 min in blocking solution (3% skim milk in
TBS). After a brief washing in TBS containing 0.05% Tween-20
(TTBS), the membrane was incubated for 1 h in a primary antibody
solution (antiserum diluted 100-fold with blocking solution). The
membrane was washed twice in citrate-buﬀered saline (20 mM citrate,
500 mM NaCl, pH 5.5) containing 0.05% Tween-20, for 5 min per
washing, and then incubated for 1 h in blocking solution containing
a 3000-fold diluted secondary antibody (GAR-HRP conjugated IgG;
Bio-Rad, Richmond, CA). Finally, the membrane was washed twice
in TTBS, once in TBS, and ﬁnally submerged in HRP color develop-
ment solution (50 ml of TBS containing 30 ll of H2O2 mixed with
0.3% of chloronaphthol in 10 ml of ice-cold methanol).
2.8. Confocal laser scanning microscopy
At the inception of the work to observe the interaction between C.
albicans and peptide via confocal laser scanning microscopy, we were
going to use FITC-labeled di-K19Hc. Prior to this microscopic experi-
ment, we ﬁrst compared the antifungal activity of the FITC-labeled di-
K19Hc against C. albicans with that of the non-labeled di-K19Hc via
comparative colony count assays. As a result, FITC-labeled di-K19Hc
was determined to have no anti-Candida activity (data not shown).
Therefore we concluded that FITC aﬀected the structure of di-K19Hc;
consequently FITC-labeled material was not appropriate for use in this
experiment. As the antiserum to 18Hc was determined to cross-react
with di-K19Hc in the Western blotting analysis (Fig. 6B), the antiserum
to 18Hc was employed in order to observe the distribution of di-K19Hc
on peptide-treated C. albicans KCTC7122, via confocal laser scanning
microscopy. One milliliter aliquots of C. albicans cells (2 · 108 cells/
ml)werewashed three timeswith PBS, and then incubated for 1 minwith
100 ll of 1 mg/ml di-K19Hc at 37 C. After a brief centrifugation, the
pelleted cells were ﬁxed for 30 min in phosphate-buﬀered 2.5% parafor-
maldehyde. The ﬁxed cells were then rinsed three times with PBS, incu-
bated for 30 min in blocking solution (PBS containing 3% gelatin) and
washed extensively with PBS, after which they were incubated for 1 h
in antiserum diluted (1:100) with PBS, containing 1% gelatin. After
washing the cells three times for 10 min each with PBS, the cells were
incubated for 1 h with FITC-conjugated goat anti-rabbit antibody
(Alexa Flour 488 Goat Anti-Rabbit, Invitrogen. USA) diluted to
1:300 in PBS containing 1% gelatin. After an additional washing in
PBS, the di-K19Hc on C. albicans was visualized and localized using
Confocal Laser Scanning Microscope FV500 (Olympus, Japan).
2.9. Scanning electron microscope (SEM)
The C. albicans KCTC7122 was resuspended in PBS, to a ﬁnal con-
centration of 108 cells/ml. 200 ll aliquots of C. albicans suspension
were incubated with 22 ll of 250 lg/ml di-K19Hc. For a control, the
same amount of C. albicans suspension was mixed with 22 ll of
0.01% acetic acid and incubated for 5 min at 30 C. The di-K19Hc-
treated or untreated C. albicans samples were then ﬁxed in 0.05 M so-
dium cacodylate buﬀer (2% glutaraldehyde, 2% paraformaldehyde, pH
7.2) for 4 h. After ﬁxation, the samples were centrifuged at 2000 rpm
and rinsed three times for 20 min each with sodium cacodylate buﬀer.
The samples were then dehydrated through a graded ethanol series
(50%, 70%, 90%, 95%, 100% ·2), for 30 in each. The samples were
freeze-dried for 8 h, and coated with a light coat of gold palladium.
The specimens were then viewed with an S-2400 scanning electron
microscope (Hitachi, Japan).3. Results
3.1. Peptides
The primary amino acid sequences of the synthetic halocidin
congeners used in this study, di-K19Hc and K19Hc, are shown
in Table 1. Table 1 also provides the sequences of P18 and
buforin II, used as the standard peptides in this study.
3.2. Antifungal activity for di-K19Hc
Table 2 shows the established MIC ranges for di-K19Hc and
the three other peptides (K19Hc, buforin II and P18) against
the four ﬁlamentous and eight yeast-phase fungi, including the
Aspergillus and Candida strains. Di-K19Hc was determined
to be more than two times stronger than its monomer
(K19Hc) against most of the fungal or yeast strains, a ﬁnding
which was consistent with the results reported in a previous
study on the antibacterial activities of halocidin congeners
[16]. Interestingly, although the three standard peptides exerted
no detectable eﬀects against the two Aspergillus strains, even at
the highest concentration (64 lg/ml) utilized in the assay, di-
K19Hc exhibited anti-Aspergillus eﬀects with an MIC of less
than 16 lg/ml. The di-K19Hc also exhibited more potent activ-
























Fig. 2. Colony count assay for the candidacidal activity of di-K19Hc.
In the long-term and short-term analyses, we treated the C. albicans
cells with di-K19Hc for the predetermined times, and spread them on
SDB agar. As a control, we added an equivalent volume of 0.01%
acetic acid containing no peptide to the control tubes. After being
cultured overnight, the viable colonies in each sample were counted.
The mean values obtained from three individual experiments were then
used in the construction of a graph. The error bars were too narrow for
the display.
Fig. 3. Potassium eﬄux assay. The C. albicans cells were treated with
either di-K19Hc or K19Hc for the predetermined times, and the
relative amounts of K+ released from the cells were measured. Each of
the symbols represents a mean value from ﬁve replicate experiments.
The error bars show the standard deviations.
W.S. Jang et al. / FEBS Letters 580 (2006) 1490–1496 1493tested fungi, and retained its anti-Candida activities, even at
elevated concentrations of salt (Table 3). Overall, our anti-
fungal assays showed that di-K19Hc was superior to other
peptides, with regard to both antifungal activity and spectrum
width.
3.3. Colony count assay for the candidacidal activity of
di-K19Hc
We performed a colony count assay in order to determine
the ability of di-K19Hc to kill C. albicans, and also to deter-
mine the time course associated with this activity. With regard
to di-K19Hc exposure, the loss of viability of C. albicans oc-
curred dose-dependently. 40 lg/ml of di-K19Hc eﬀected a
reduction in the number of viable C. albicans cells by more
than 4 log10 after 10 min of incubation, and slightly aﬀected
fungal viability during further incubation (Fig. 2, long-term).
Therefore, we attempted to assess the candidacidal eﬀects of
di-K19Hc within a 10-min incubation period. Short-term anal-
ysis showed that the minimum number of viable colonies was
achieved after 30 s of incubation, and reached a plateau there-
after (Fig. 2, short-term), thereby illustrating the marked
rapidity with which di-K19Hc killed the C. albicans cells: its
candidacidal activity was completed within 30 s.
3.4. Eﬀects of di-K19Hc on the integrity of the C. albicans
membrane
As many antimicrobial peptides have been determined to ex-
ert their eﬀects via the induction of permeability changes in the
membranes of susceptible microbes, we attempted to charac-
terize the eﬀects of di-K19Hc on the integrity of C. albicans
membranes, by monitoring the permeability of the membranes
to intracellular K+, and by recording the uptake of PI, a DNA-
staining ﬂuorescent probe, into the C. albicans cells. Fig. 3
shows the content of K+ eﬄux from C. albicans treated with
di-K19Hc for the predetermined incubation time. An esti-
mated 88% ± 2% (n = 5) of the total intracellular K+ was re-
leased after 10 min of incubation in every one of these
experiments, and the percentage of K+ eﬄux remained con-
stant during further incubation (Fig. 3, long-term). In addi-
tion, our short-term test showed that the amount of released
K+ began to increase rapidly at 30 s after the initiation of pep-
tide treatment (Fig. 3, short-term). The time course associated
with the K+ eﬄux from the C. albicans treated with di-K19Hc
exhibited a pattern consistent with the results obtained from
the colony count assay for the candidacidal activity of di-
K19Hc. Therefore, according to these results, we concluded
that di-K19Hc induced an immediate and massive eﬄux of
K+ from C. albicans. Fig. 4 shows the results of the intracellu-
lar PI measurements, which were analyzed via ﬂow cytometry.
The majority of the C. albicans cells were labeled ﬂuorescentlyTable 3
Eﬀect of salt on candidacidal activity of di-K19Hc
Peptides Candida albicans KCTC71 22
NaCl: 0 mM 100 mM 200 mM
Di-K19Hc 2–4 4–8 8–16
K19Hc 8–16 16–32 32–64
P18 1–2 8–16 16–32
Buforin II 32–64 >64 >64
The MIC values are shown in lg/ml.after 10 min of incubation with 3.12 lg/ml di-K19Hc, thereby
indicating that di-K19Hc induced the inﬂux of PI into the cells.
3.5. Speciﬁc binding of di-K19Hc to the component of fungal cell
wall
In order to investigate if di-K19Hc speciﬁcally binds to fun-
gal cell surface, eﬀects of several polysaccharides composing of
fungal cell wall on the anti-Candida activity of di-K19Hc were
examined (Fig. 5). The constant amount of di-K19Hc was
incubated at diﬀerent concentrations of laminarin (b-1,3-glu-
can), mannan or pustulan (b-1,6-glucan), and then the mixture
was tested for anti-Candida activity in agar diﬀusion assay. As
a result, its activity was signiﬁcantly reduced as the amount of
laminarin increased in the mixture. By contrast, neither man-
nan nor b-1,6-glucan aﬀected the anti-Candida activity of di-
K19Hc. These results indicate that laminarin prevented
Fig. 4. Flow cytometric analysis. C. albicans cells were treated with di-
K19Hc and stained with PI. Cellular ﬂuorescence was then analyzed
via FACScan ﬂow cytometry. The increments of the log ﬂuorescence
signal represent the uptake of PI by the yeast cells. Cells were treated
with no peptide (A), K19Hc (B), and di-K19Hc (C).
1494 W.S. Jang et al. / FEBS Letters 580 (2006) 1490–1496di-K19Hc from interacting with the cell surface of C. albicans,
resulting in the abrogation the di-K19Hc-induced antifungal
activity in a dose-dependent manner. Therefore it was con-
cluded that di-K19Hc bound to C. albicans cells via a speciﬁc
interaction with b-1,3-glucan, thereby exerted its antifungal
eﬀects.
3.6. Microscopic observation
We used a rabbit antiserum raised against 18Hc and FITC-
labeled secondary antibody in order to observe the interaction
occurring between C. albicans and di-K19Hc, via confocal la-
ser scanning microscopy. In order to examine the target sites of
di-K19Hc in C. albicans, we have treated the cells with di-Fig. 5. Speciﬁc binding of di-K19Hc to laminarin. Binding/radial
diﬀusion assay was performed by mixing various amounts of pustulan,
laminarin or mannan with 1.25 lg of di-K19Hc in a ﬁnal volume of
5 ll. The mixtures of di-K19Hc with laminarin, pustulan or mannan
were introduced into the wells of radial diﬀusion assay plates seeded
with C. albicans ACTC7121, which was conﬁrmed as a highly
susceptible yeast to di-K19Hc. The left panel shows photo of gel in
radial diﬀusion assay. Numbers represent the polysaccharide concen-
trations (mg/ml) of the mixture loaded in each well. lam, laminarin;
pus, pustulan; man, mannan. 5 ll of 250 lg/ml di-K19Hc was used for
polysaccharides-free control. In the right panel, the anti-Candida
activities of di-K19Hc in the mixture were graphed against concentra-
tion of polysaccharides. Diameters of clearing zone have been
expressed in units (1 mm = 10 U). The error bars were too small to
be expressed.K19Hc, with the antiserum and the FITC-labeled secondary
antibody sequentially, after which the samples were visualized
under confocal microscopy. The FITC-labeled secondary anti-
body was determined to have accumulated on the cell surface
(Fig. 6D), thereby indicating that di-K19Hc acts on the mem-
branes of the fungal cells, and induces the alteration of the cell
membrane. We also evaluated, via scanning electron micros-
copy, the morphological changes in the C. albicans cells in-
duced by di-K19Hc treatment. Whereas the untreated cells
exhibited normal, smooth surfaces (Fig. 7A), the cell walls of
the C. albicans that had been incubated with di-K19Hc re-
vealed a series of dramatic alterations, including surface
roughening and disruption, within 5 min of exposure
(Fig. 7B and C). We considered this to be a strong indication
that the membrane had been modiﬁed substantially by di-
K19Hc, and surmised that this might constitute a critical step
in the compound’s candidacidal eﬀects.4. Discussion
For the last forty years, over 100 natural peptides have been
determined to exhibit activities against pathogenic fungi. These
compounds have been isolated from a wide variety of organ-
isms, including bacteria, fungi, plants, invertebrates, and verte-
brates [26]. However, the majority of these compounds have
not been used in clinical trials, due to defects in their anti-
fungal activities, or in the breadth of their spectra. The search
for such antifungal peptides continues, in the hopes of locating
an eﬀective candidate for the development of a new type of
antibiotic [27,28]. We recently began to study the antimicrobial
activity of halocidin, again in the hope that it could be devel-
oped into a novel therapeutic agent, which might prove useful
in the treatment of several incurable infectious diseases. Previ-Fig. 6. Western blot analysis and Confocal laser scanning microscopy.
Western blotting analysis indicated that the antiserum to 18Hc
recognized di-K19Hc, the primary sequence of which is identical to
18Hc in terms of its 18/19 residues. (A) An acid urea–PAGE gel
stained with Coomassie’s blue. (B) Western blot analysis conducted
with a duplicate gel of (A). Lane 1, 18Hc; lane 2, di-K19Hc. C. albicans
cells were incubated with di-K19Hc, then treated with antiserum to
18Hc and FITC-labeled secondary antibody. The cells were then
visualized via confocal laser scanning microscopy. For the control
experiment, C. albicans cells which had not been treated with di-
K19Hc were incubated with antiserum to 18Hc, and treated with
FITC-labeled secondary antibody. (C) Phase-contrast image of C.
albicans treated with di-K19Hc. (D) Fluorescent image of C. albicans
treated with di-K19Hc. (E) Phase-contrast image of control sample.
(F) Fluorescent image of control sample.
Fig. 7. Scanning electron microscopy. Scanning electron micrographs revealed that the surface of the untreated C. albicans cells were smooth (A) and
the surfaces of the di-K19Hc-treated cells were ruﬄed, and became rugged (B,C).
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signed and tested with regard to their antibacterial activities
[16]. As a result, di-K19Hc emerged as the most promising can-
didate for the development of a new antibiotic against antibi-
otic-resistant bacteria. As in the case of many other peptides,
including cecropin [29], magainin II [30], and protegrin [31],
all of which exhibited antifungal and antibacterial eﬀects, di-
K19Hc was also anticipated to exhibit antifungal properties.
Hence, in this study, we have assessed the activity of di-
K19Hc against a panel of fungi, in a series of assays that were
conducted in accordance with NCCLS procedures. Our MIC
data (Tables 2 and 3) indicated that di-K19Hc retained an
antifungal activity that might be suitable for the treatment of
fungal diseases. Accordingly, it has become clear that di-
K19Hc was an active peptide possessing both antifungal and
antibacterial eﬃcacy, against a wide range of pathogenic mi-
crobes. As marine animals live in a habitat characterized by
high salinity, it has been often postulated that antimicrobial
peptides originating from marine sources may maintain their
activities in conditions of high salinity. Actually, certain anti-
microbial peptides, such as styelins from the tunicate [12]
and oncorhyncin III from rainbow trout [32], have been shown
to exert their eﬀects in the presence of 300 and 547 mM NaCl,
respectively. Considering the results obtained from the previ-
ous [16] and the present studies, it has become evident that
di-K19Hc was also capable of exerting its antimicrobial activ-
ity under elevated salt concentration conditions, although the
structural motifs of di-K19Hc required for its salt-resistant
activity remain to be elucidated.
In order to elucidate the mechanisms underlying di-K19Hc
antifungal eﬀects, we attempted to determine the manner in
which di-K19Hc actually carries out the destruction of C. albi-
cans. We performed colony count assays in order to determine
the time required for the compound to kill C. albicans. With
regard to the results reported in studies of the time-dependent
bacteria-killing kinetics of antimicrobial peptides, it has gener-
ally been reported that these compounds exert their antibacte-
rial eﬀects within minutes of exposure to bacteria [33–35]. This
rapid killing process has been most plausibly attributed to the
action of these compounds on the bacterial membranes [36,37].
Our study also showed that di-K19Hc was capable of killing C.
albicans within 30 s (Fig. 2). This result led us to hypothesize
that di-K19Hc might act principally on the membrane of C.
albicans cells, inducing cell lysis. In accordance with our
hypothesis, the treatment of C. albicans cells with di-K19Hc in-
duced a major eﬄux of intracellular K+ (Fig. 3) or a major in-
ﬂux of PI (Fig. 4), demonstrating that di-K19Hc executed its
anti-candida eﬀects via binding to the surface of the cells, fol-
lowed by the formation of membrane pores. Interestingly,
our results indicated that the antifungal activity of theK19Hc dimer (di-K19Hc) was over two times as strong as that
of the monomer against all tested fungi, except for the P. grisea
species. As reported in other studies involving the disulﬁde-
dimerized analogues of magainin II [38,39] and melittin [40],
it has been surmised that di-K19Hc may induce the formation
of larger pores in a fungal membrane with a longer lifetime
than is associated with K19Hc, thereby resulting in more pro-
found antifungal activity. In addition, it was veriﬁed that bind-
ing of di-K19Hc to the fungal surface occurred via speciﬁc
interaction with b-1,3-glucan, which is one of components of
the fungal cell wall (Fig. 5). Also, it was strongly supported
by the observations made under confocal (Fig. 6D) and scan-
ning electron microscopy (Fig. 7). Taken together, the anti-
fungal activity of di-K19Hc was concluded to result from the
disintegration of the cell membrane rather than from any eﬀect
on the physiology of the cells.
Because some of antimicrobial peptides physically attack the
microbial membranes, thereby killing even microbes that are
equipped with antibiotic-resistant mechanisms, they have been
the focus of increasing interest, and are being heralded as
excellent candidates in the search for new types of antibiotics
[41,42]. Among these compounds, di-K19Hc appears to be
one of the most promising as a possible therapeutic agent for
infections caused by pathogenic fungi or bacteria that are resis-
tant to currently available drugs.Acknowledgments: This work was supported by a Grant (KRF 2004-
015-C00521) from the Korea Research Foundation.References
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